The field of oncology has seen significant advancements in understanding and treating various types of cancers. One such area is the study of Pulmonary Neuroendocrine Tumors (NETs), a rare and heterogeneous type of cancer that develops from cells of the neuroendocrine system. These tumors can occur in many parts of the body, but they most commonly arise from the gastrointestinal tract, pancreas, and lungs. They can be classified as functional or non-functional tumors, according to their ability to produce and secrete hormones and biogenic amines. The treatment of Pulmonary NETs depends on several factors, including the type, location, and stage of the tumor. However, the diagnosis and treatment of pulmonary NETs are complex, due to their relative rarity and heterogeneous behavior.
The goal of this research topic is to provide a platform to discuss the most relevant advances in the field of Pulmonary NETs. It aims to provide a collection of high-quality Mini-Reviews, to act as a valuable resource for academics and clinicians to stay up-to-date with the key advances in the pathogenesis, diagnosis, and treatment of pulmonary neuroendocrine tumors. This includes understanding the epidemiological evolution, clinical characteristics, and identifying clinically relevant biomarkers, including predictive factors of response and survival.
To gather further insights into the complexities of Pulmonary NETs, we welcome Mini-Reviews adressing, but not limited to, the following themes:
● Advances in diagnosis and molecular classification of pulmonary neuroendocrine tumors
● Epidemiological evolution and clinical characteristics of pulmonary neuroendocrine tumors
● Clinically relevant biomarkers, including predictive factors of response and survival
● Therapeutic strategies
● Characterization of (hereditary) syndromes associated with pulmonary neuroendocrine tumors, including diffuse neuroendocrine cell hyperplasia (DIPNECH).
Please note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords:
Neuroendocrine tumors, biomarker, cancer therapy, tumor classification, pulmonary
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
The field of oncology has seen significant advancements in understanding and treating various types of cancers. One such area is the study of Pulmonary Neuroendocrine Tumors (NETs), a rare and heterogeneous type of cancer that develops from cells of the neuroendocrine system. These tumors can occur in many parts of the body, but they most commonly arise from the gastrointestinal tract, pancreas, and lungs. They can be classified as functional or non-functional tumors, according to their ability to produce and secrete hormones and biogenic amines. The treatment of Pulmonary NETs depends on several factors, including the type, location, and stage of the tumor. However, the diagnosis and treatment of pulmonary NETs are complex, due to their relative rarity and heterogeneous behavior.
The goal of this research topic is to provide a platform to discuss the most relevant advances in the field of Pulmonary NETs. It aims to provide a collection of high-quality Mini-Reviews, to act as a valuable resource for academics and clinicians to stay up-to-date with the key advances in the pathogenesis, diagnosis, and treatment of pulmonary neuroendocrine tumors. This includes understanding the epidemiological evolution, clinical characteristics, and identifying clinically relevant biomarkers, including predictive factors of response and survival.
To gather further insights into the complexities of Pulmonary NETs, we welcome Mini-Reviews adressing, but not limited to, the following themes:
● Advances in diagnosis and molecular classification of pulmonary neuroendocrine tumors
● Epidemiological evolution and clinical characteristics of pulmonary neuroendocrine tumors
● Clinically relevant biomarkers, including predictive factors of response and survival
● Therapeutic strategies
● Characterization of (hereditary) syndromes associated with pulmonary neuroendocrine tumors, including diffuse neuroendocrine cell hyperplasia (DIPNECH).
Please note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords:
Neuroendocrine tumors, biomarker, cancer therapy, tumor classification, pulmonary
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.